scholarly journals Cerebral Venous Thrombosis Revealing Primary Sjögren Syndrome: Report of 2 Cases

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
A. Mercurio ◽  
M. Altieri ◽  
V. M. Saraceni ◽  
T. Paolucci ◽  
G. L. Lenzi

Sjögren syndrome (SS) is an autoimmune disease of the exocrine glands, characterized by focal lymphocytic infiltration and destruction of these glands. Neurologic complications are quite common, mainly involving the peripheral nervous system (PNS). The most common central nervous system (CNS) manifestations are myelopathy and microcirculation vasculitis. However, specific diagnostic criteria for CNS SS are still lacking. We report two cases of primary SS in which the revealing symptom was cerebral venous thrombosis (CVT) in the absence of genetic or acquired thrombophilias.

1995 ◽  
Vol 127 (6) ◽  
pp. 961-963 ◽  
Author(s):  
Takeshi Ohtsuka ◽  
Yuriko Saito ◽  
Motohiro Hasegawa ◽  
Masaru Tatsuno ◽  
Seiji Takita ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e84605 ◽  
Author(s):  
Manuela Morreale ◽  
Pasquale Marchione ◽  
Patrizia Giacomini ◽  
Simona Pontecorvo ◽  
Massimo Marianetti ◽  
...  

2021 ◽  
pp. jrheum.201171
Author(s):  
George Markousis-Mavrogenis ◽  
Sophie I. Mavrogeni

Sjögren syndrome (SS) is a systemic autoimmune disease typically characterized by inflammatory involvement of the exocrine glands1. The association of SS with an increased risk of cardiovascular disease (CVD) including manifestations such as stroke and myocardial infarction has been demonstrated by numerous previous studies1.


Proceedings ◽  
2019 ◽  
Vol 35 (1) ◽  
pp. 39
Author(s):  
Setti ◽  
Sandri ◽  
Tarentini ◽  
Panari ◽  
Mucci ◽  
...  

Primary Sjögren Syndrome (pSS) is a multisystem autoimmune disease which mainly involves exocrine glands, such as salivary and lacrimal. [...]


2014 ◽  
Vol 35 (2) ◽  
pp. 289-294 ◽  
Author(s):  
Isabel Moreira ◽  
Filipa Teixeira ◽  
Ana Martins Silva ◽  
Carlos Vasconcelos ◽  
Fátima Farinha ◽  
...  

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 1097.1-1097
Author(s):  
M.M. Mayer ◽  
S.D. Velez ◽  
F. Zazzetti ◽  
L. Galván ◽  
G. Bennasar ◽  
...  

2020 ◽  
Vol 29 (157) ◽  
pp. 200021
Author(s):  
Fabrizio Luppi ◽  
Marco Sebastiani ◽  
Nicola Sverzellati ◽  
Alberto Cavazza ◽  
Carlo Salvarani ◽  
...  

Primary Sjogren syndrome (pSS) is a systemic autoimmune disease characterised by lymphocytic infiltration of exocrine glands and by a number of systemic manifestations, including those regarding the lung. Pulmonary involvement in pSS includes interstitial lung disease (ILD) and airway disease, together with lymphoproliferative disorders.Patients with pSS-ILD report impaired health-related quality of life and a higher risk of death, suggesting the importance of early diagnosis and treatment of this type of pulmonary involvement. In contrast, airway disease usually has little effect on respiratory function and is rarely the cause of death in these patients.More rare disorders can be also identified, such as pleural effusion, cysts or bullae.Up to date, available data do not allow us to establish an evidence-based treatment strategy in pSS-ILD. No data are available regarding which patients should be treated, the timing to start therapy and better therapeutic options. The lack of knowledge about the natural history and prognosis of pSS-ILD is the main limitation to the development of clinical trials or shared recommendations on this topic. However, a recent trial showed the efficacy of the antifibrotic drug nintedanib in slowing progression of various ILDs, including those in pSS patients.


Sign in / Sign up

Export Citation Format

Share Document